Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity

Vaccine

Volumn 28, Issue 6, 2010, Pages 1642-1654

  Barnoy, S ^a   Jeong, K I ^b   Helm, R F ^c   Suvarnapunya, A E ^a   Ranallo, R T ^a   Tzipori, S ^b   Venkatesan, M M ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b TUFTS UNIVERSITY   (United States)

^c VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Live attenuated vaccine candidates; Shigella sonnei; WRSs2; WRSs3

Indexed keywords

BACTERIAL VACCINE; ENTEROTOXIN; LIPOPOLYSACCHARIDE; LIVE VACCINE; UNCLASSIFIED DRUG; WRSS2 VACCINE; WRSS3 VACCINE;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; DIARRHEA; HUMAN; HUMAN CELL; IMMUNOGENICITY; NONHUMAN; PIGLET; PRIORITY JOURNAL; SHIGELLA FLEXNERI; SHIGELLA SONNEI;

ANIMALS; BACTERIAL PROTEINS; CELL LINE; CRICETINAE; ENTEROTOXINS; GENE DELETION; GUINEA PIGS; HUMANS; LIPID A; MALE; SHIGELLA SONNEI; SHIGELLA VACCINES; SWINE; TRANSCRIPTION FACTORS; VACCINES, ATTENUATED;

EID: 75249084778     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.001     Document Type: Article

References (85)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bulletin of the World Health Organization 77 8 (1999) 651-666
2. Niyogi S.K. Increasing antimicrobial resistance-an emerging problem in the treatment of shigellosis. Clinical Microbiology and Infection 13 December (12) (2007) 1141-1143
3. Morpeth S.C., and Thielman N.M. Diarrhea in patients with AIDS. Current Treatment Options in Gastroenterology 9 February (1) (2006) 23-37
4. Iwalokun B.A., Gbenle G.O., Smith S.I., Ogunledun A., Akinsinde K.A., and Omonigbehin E.A. Epidemiology of shigellosis in Lagos, Nigeria: trends in antimicrobial resistance. Journal of Health, Population, and Nutrition 19 September (3) (2001) 183-190
5. Hien B.T., Trang do T., Scheutz F., Cam P.D., Molbak K., and Dalsgaard A. Diarrhoeagenic Escherichia coli and other causes of childhood diarrhoea: a case-control study in children living in a wastewater-use area in Hanoi, Vietnam. Journal of Medical Microbiology 56 August (Pt 8) (2007) 1086-1096
6. Morgan O., Crook P., Cheasty T., Jiggle B., Giraudon I., Hughes H., et al. Shigella sonnei outbreak among homosexual men, London. Emerging Infectious Diseases 12 September (9) (2006) 1458-1460
7. Mammina C., Aleo A., Romani C., and Nastasi A. Shigella sonnei biotype G carrying class 2 integrons in southern Italy: a retrospective typing study by pulsed field gel electrophoresis. BMC Infectious Diseases 6 (2006) 117
8. Gaynor K., Park S.Y., Kanenaka R., Colindres R., Mintz E., Ram P.K., et al. International foodborne outbreak of Shigella sonnei infection in airline passengers. Epidemiology and Infection 4 January (2008) 1-7
9. Terajima J., Tosaka N., Ueno K., Nakashima K., Kitsutani P., Gaynor M.K., et al. Shigella sonnei outbreak among Japanese travelers returning from Hawaii. Japanese Journal of Infectious Diseases 59 August (4) (2006) 282-283
10. Gupta A., Polyak C.S., Bishop R.D., Sobel J., and Mintz E.D. Laboratory-confirmed shigellosis in the United States, 1989-2002: epidemiologic trends and patterns. Clinical Infectious Diseases 38 May (10) (2004) 1372-1377
11. Wei H.L., Wang Y.W., Li C.C., Tung S.K., and Chiou C.S. Epidemiology and evolution of genotype and antimicrobial resistance of an imported Shigella sonnei clone circulating in central Taiwan. Diagnostic Microbiology and Infectious Disease 58 August (4) (2007) 469-475
12. Seol S.Y., Kim Y.T., Jeong Y.S., Oh J.Y., Kang H.Y., Moon D.C., et al. Molecular characterization of antimicrobial resistance in Shigella sonnei isolates in Korea. Journal of Medical Microbiology 55 July (Pt 7) (2006) 871-877
13. Ranjbar R., Aleo A., Giammanco G.M., Dionisi A.M., Sadeghifard N., and Mammina C. Genetic relatedness among isolates of Shigella sonnei carrying class 2 integrons in Tehran, Iran, 2002-2003. BMC Infectious Diseases 7 (2007) 62
14. Penatti M.P., Hollanda L.M., Nakazato G., Campos T.A., Lancellotti M., Angellini M., et al. Epidemiological characterization of resistance and PCR typing of Shigella flexneri and Shigella sonnei strains isolated from bacillary dysentery cases in Southeast Brazil. Brazilian Journal of Medical and Biological Research = Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica 40 February (2) (2007) 249-258
15. Matar G.M., Jaafar R., Sabra A., Hart C.A., Corkill J.E., Dbaibo G.S., et al. First detection and sequence analysis of the bla-CTX-M-15 gene in Lebanese isolates of extended-spectrum-beta-lactamase-producing Shigella sonnei. Annals of Tropical Medicine and Parasitology 101 September (6) (2007) 511-517
16. Xiong Z., Li T., Xu Y., and Li J. Detection of CTX-M-14 extended-spectrum beta-lactamase in Shigella sonnei isolates from China. The Journal of Infection 55 November (5) (2007) e125-e128
17. Brian M.J., Van R., Townsend I., Murray B.E., Cleary T.G., and Pickering L.K. Evaluation of the molecular epidemiology of an outbreak of multiply resistant Shigella sonnei in a day-care center by using pulsed-field gel electrophoresis and plasmid DNA analysis. Journal of Clinical Microbiology 31 August (8) (1993) 2152-2156
18. Garrett V., Bornschlegel K., Lange D., Reddy V., Kornstein L., Kornblum J., et al. A recurring outbreak of Shigella sonnei among traditionally observant Jewish children in New York City: the risks of daycare and household transmission. Epidemiology and Infection 134 December (6) (2006) 1231-1236
19. Sobel J., Cameron D.N., Ismail J., Strockbine N., Williams M., Diaz P.S., et al. A prolonged outbreak of Shigella sonnei infections in traditionally observant Jewish communities in North America caused by a molecularly distinct bacterial subtype. The Journal of Infectious Diseases 177 May (5) (1998) 1405-1409
20. Shimosako J., Onaka T., Yamanouchi M., Yokota M., Nakamura T., Fujii F., et al. An outbreak of extended-spectrum beta-lactamase (ESBL)-producing Shigella sonnei at a day care nursery in Sakai City, 2006. Japanese Journal of Infectious Diseases 60 November (6) (2007) 408-409
21. von Seidlein L., Kim D.R., Ali M., Lee H., Wang X., Thiem V.D., et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Medicine 3 September (9) (2006) e353
22. Dubois V., Parizano M.P., Arpin C., Coulange L., Bezian M.C., and Quentin C. High genetic stability of integrons in clinical isolates of Shigella spp. of worldwide origin. Antimicrobial Agents and Chemotherapy 51 April (4) (2007) 1333-1340
23. Pan J.C., Ye R., Meng D.M., Zhang W., Wang H.Q., and Liu K.Z. Molecular characteristics of class 1 and class 2 integrons and their relationships to antibiotic resistance in clinical isolates of Shigella sonnei and Shigella flexneri. The Journal of Antimicrobial Chemotherapy 58 August (2) (2006) 288-296
24. Ahmed A.M., Furuta K., Shimomura K., Kasama Y., and Shimamoto T. Genetic characterization of multidrug resistance in Shigella spp. from Japan. Journal of Medical Microbiology 55 December (Pt 12) (2006) 1685-1691
25. Lefort A., Arlet G., Join-Lambert O.F., Lecuit M., and Lortholary O. Novel extended-spectrum beta-lactamase in Shigella sonnei. Emerging Infectious Diseases 13 April (4) (2007) 653-654
26. Boumghar-Bourtchai L., Mariani-Kurkdjian P., Bingen E., Filliol I., Dhalluin A., Ifrane S.A., et al. Macrolide-resistant Shigella sonnei. Emerging Infectious Diseases 14 August (8) (2008) 1297-1299
27. Jennison A.V., and Verma N.K. Shigella flexneri infection: pathogenesis and vaccine development. FEMS Microbiology Reviews 28 February (1) (2004) 43-58
28. Venkatesan M.M., and Ranallo R.T. Live-attenuated Shigella vaccines. Expert Review of Vaccines 5 October (5) (2006) 669-686
29. Ranallo R.T., Fonseka C.P., Cassels F., Srinivasan J., and Venkatesan M.M. Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infection and Immunity 73 January (1) (2005) 258-267
30. Ranallo R.T., Barnoy S., Thakkar S., Urick T., and Venkatesan M.M. Developing live Shigella vaccines using lambda Red recombineering. FEMS Immunology and Medical Microbiology 47 August (3) (2006) 462-469
31. Oaks E.V., and Turbyfill K.R. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine 24 March (13) (2006) 2290-2301
32. Ranallo R.T., Thakkar S., Chen Q., and Venkatesan M.M. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. Vaccine 25 March (12) (2007) 2269-2278
33. Kotloff K.L., Simon J.K., Pasetti M.F., Sztein M.B., Wooden S.L., Livio S., et al. Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media. Human Vaccines 3 November-December (6) (2007) 268-275
34. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., and Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nature Reviews 5 July (7) (2007) 540-553
35. Pozsgay V., Kubler-Kielb J., Schneerson R., and Robbins J.B. Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice. Proceedings of the National Academy of Sciences of the United States of America 104 September (36) (2007) 14478-14482
36. Passwell J.H., Ashkenazi S., Harlev E., Miron D., Ramon R., Farzam N., et al. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. The Pediatric Infectious Disease Journal 22 August (8) (2003) 701-706
37. Chowers Y., Kirschner J., Keller N., Barshack I., Bar-Meir S., Ashkenazi S., et al. O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative. Proceedings of the National Academy of Sciences of the United States of America 104 February (7) (2007) 2396-2401
38. Sadorge C., Ndiaye A., Beveridge N., Frazer S., Giemza R., Jolly N., et al. Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers. Vaccine 26 February (7) (2008) 978-987
39. Kotloff K.L., Taylor D.N., Sztein M.B., Wasserman S.S., Losonsky G.A., Nataro J.P., et al. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infection and Immunity 70 April (4) (2002) 2016-2021
40. Orr N., Katz D.E., Atsmon J., Radu P., Yavzori M., Halperin T., et al. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infection and Immunity 73 December (12) (2005) 8027-8032
41. Lett M.C., Sasakawa C., Okada N., Sakai T., Makino S., Yamada M., et al. virG, a plasmid-coded virulence gene of Shigella flexneri: identification of the virG protein and determination of the complete coding sequence. Journal of Bacteriology 171 January (1) (1989) 353-359
42. Bernardini M.L., Mounier J., d'Hauteville H., Coquis-Rondon M., and Sansonetti P.J. Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin. Proceedings of the National Academy of Sciences of the United States of America 86 May (10) (1989) 3867-3871
43. Sansonetti P.J., Arondel J., Fontaine A., d'Hauteville H., and Bernardini M.L. OmpB (osmo-regulation) and icsA (cell-to-cell spread) mutants of Shigella flexneri: vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine 9 June (6) (1991) 416-422
44. Yoshikawa M., Sasakawa C., Okada N., Takasaka M., Nakayama M., Yoshikawa Y., et al. Construction and evaluation of a virG thyA double mutant of Shigella flexneri 2a as a candidate live-attenuated oral vaccine. Vaccine 13 15 (1995) 1436-1440
45. Coster T.S., Hoge C.W., VanDeVerg L.L., Hartman A.B., Oaks E.V., Venkatesan M.M., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infection and Immunity 67 July (7) (1999) 3437-3443
46. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infection and Immunity 72 February (2) (2004) 923-930
47. Hartman A.B., and Venkatesan M.M. Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Infection and Immunity 66 September (9) (1998) 4572-4576
48. McKenzie R., Venkatesan M.M., Wolf M.K., Islam D., Grahek S., Jones A.M., et al. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine 26 June (26) (2008) 3291-3296
49. Fasano A., Noriega F.R., Maneval Jr. D.R., Chanasongcram S., Russell R., Guandalini S., et al. Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. The Journal of Clinical Investigation 95 June (6) (1995) 2853-2861
50. Nataro J.P., Seriwatana J., Fasano A., Maneval D.R., Guers L.D., Noriega F., et al. Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infection and Immunity 63 December (12) (1995) 4721-4728
51. Noriega F.R., Liao F.M., Formal S.B., Fasano A., and Levine M.M. Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypes. The Journal of Infectious Diseases 172 November (5) (1995) 1408-1410
52. Taylor D.N., Echeverria P., Sethabutr O., Pitarangsi C., Leksomboon U., Blacklow N.R., et al. Clinical and microbiologic features of Shigella and enteroinvasive Escherichia coli infections detected by DNA hybridization. Journal of Clinical Microbiology 26 July (7) (1988) 1362-1366
53. Buchrieser C., Glaser P., Rusniok C., Nedjari H., D'Hauteville H., Kunst F., et al. The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of Shigella flexneri. Molecular Microbiology 38 November (4) (2000) 760-771
54. Kotloff K.L., Pasetti M.F., Barry E.M., Nataro J.P., Wasserman S.S., Sztein M.B., et al. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. The Journal of Infectious Diseases 190 November (10) (2004) 1745-1754
55. Venkatesan M.M., Goldberg M.B., Rose D.J., Grotbeck E.J., Burland V., and Blattner F.R. Complete DNA sequence and analysis of the large virulence plasmid of Shigella flexneri. Infection and Immunity 69 May (5) (2001) 3271-3285
56. Caroff M., and Karibian D. Structure of bacterial lipopolysaccharides. Carbohydrate Research 338 November (23) (2003) 2431-2447
57. Kumazawa Y., Nakatsuka M., Takimoto H., Furuya T., Nagumo T., Yamamoto A., et al. Importance of fatty acid substituents of chemically synthesized lipid A-subunit analogs in the expression of immunopharmacological activity. Infection and Immunity 56 January (1) (1988) 149-155
58. D'Hauteville H., Khan S., Maskell D.J., Kussak A., Weintraub A., Mathison J., et al. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. Journal of Immunology 168 May (10) (2002) 5240-5251
59. Karow M., and Georgopoulos C. Isolation and characterization of the Escherichia coli msbB gene, a multicopy suppressor of null mutations in the high-temperature requirement gene htrB. Journal of Bacteriology 174 February (3) (1992) 702-710
60. Clementz T., Zhou Z., and Raetz C.R. Function of the Escherichia coli msbB gene, a multicopy suppressor of htrB knockouts, in the acylation of lipid A. Acylation by MsbB follows laurate incorporation by HtrB. The Journal of Biological Chemistry 272 April (16) (1997) 10353-10360
61. Somerville Jr. J.E., Cassiano L., and Darveau R.P. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infection and Immunity 67 December (12) (1999) 6583-6590
62. Kim S.H., Jia W., Bishop R.E., and Gyles C. An msbB homologue carried in plasmid pO157 encodes an acyltransferase involved in lipid A biosynthesis in Escherichia coli O157:H7. Infection and Immunity 72 February (2) (2004) 1174-1180
63. Goldman S.R., Tu Y., and Goldberg M.B. Differential regulation by magnesium of the two MsbB paralogs of Shigella flexneri. Journal of Bacteriology 190 May (10) (2008) 3526-3537
64. Murphy K.C., and Campellone K.G. Lambda Red-mediated recombinogenic engineering of enterohemorrhagic and enteropathogenic E. coli. BMC Molecular Biology 4 December (2003) 11
65. Uzzau S., Figueroa-Bossi N., Rubino S., and Bossi L. Epitope tagging of chromosomal genes in Salmonella. Proceedings of the National Academy of Sciences of the United States of America 98 December (26) (2001) 15264-15269
66. Westphal O., Luderitz O., Rietschel E.T., and Galanos C. Bacterial lipopolysaccharide and its lipid A component: some historical and some current aspects. Biochemical Society Transactions 9 June (3) (1981) 191-195
67. El Hamidi A., Tirsoaga A., Novikov A., Hussein A., and Caroff M. Microextraction of bacterial lipid A: easy and rapid method for mass spectrometric characterization. Journal of Lipid Research 46 August (8) (2005) 1773-1778
68. Donohue-Rolfe A., Kondova I., Oswald S., Hutto D., and Tzipori S. Escherichia coli O157:H7 strains that express Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isotypes producing only Stx1 or both Stx1 and Stx2. The Journal of Infectious Diseases 181 May (5) (2000) 1825-1829
69. Bochner B.R., Huang H.C., Schieven G.L., and Ames B.N. Positive selection for loss of tetracycline resistance. Journal of Bacteriology 143 August (2) (1980) 926-933
70. Jiang Y., Yang F., Zhang X., Yang J., Chen L., Yan Y., et al. The complete sequence and analysis of the large virulence plasmid pSS of Shigella sonnei. Plasmid 54 September (2) (2005) 149-159
71. Jones J.W., Shaffer S.A., Ernst R.K., Goodlett D.R., and Turecek F. Determination of pyrophosphorylated forms of lipid A in Gram-negative bacteria using a multivaried mass spectrometric approach. Proceedings of the National Academy of Sciences of the United States of America 105 September (35) (2008) 12742-12747
72. Sereny B. Experimental shigella keratoconjunctivitis; a preliminary report. Acta Microbiologica Academiae Scientiarum Hungaricae 2 3 (1955) 293-296
73. Sansonetti P.J., Kopecko D.J., and Formal S.B. Shigella sonnei plasmids: evidence that a large plasmid is necessary for virulence. Infection and Immunity 34 October (1) (1981) 75-83
74. McKenzie R., Walker R.I., Nabors G.S., Van De Verg L.L., Carpenter C., Gomes G., et al. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine 24 May (18) (2006) 3735-3745
75. Ashkenazi S., Passwell J.H., Harlev E., Miron D., Dagan R., Farzan N., et al. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. The Journal of Infectious Diseases 179 June (6) (1999) 1565-1568
76. Cohen D., Ashkenazi S., Green M.S., Gdalevich M., Robin G., Slepon R., et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349 January (9046) (1997) 155-159
77. Trucksis M., Conn T.L., Fasano A., and Kaper J.B. Production of Vibrio cholerae accessory cholera enterotoxin (Ace) in the yeast Pichia pastoris. Infection and Immunity 65 December (12) (1997) 4984-4988
78. Loppnow H., Brade H., Durrbaum I., Dinarello C.A., Kusumoto S., Rietschel E.T., et al. IL-1 induction-capacity of defined lipopolysaccharide partial structures. Journal of Immunology 142 May (9) (1989) 3229-3238
79. Loppnow H., Durrbaum I., Brade H., Dinarello C.A., Kusumoto S., Rietschel E.T., et al. Lipid A, the immunostimulatory principle of lipopolysaccharides?. Advances in Experimental Medicine and Biology 256 (1990) 561-566
80. Medzhitov R., and Janeway Jr. C. The Toll receptor family and microbial recognition. Trends in Microbiology 8 October (10) (2000) 452-456
81. Medzhitov R., and Janeway Jr. C. Innate immune recognition: mechanisms and pathways. Immunological Reviews February (173) (2000) 89-97
82. Schromm A.B., Brandenburg K., Loppnow H., Moran A.P., Koch M.H., Rietschel E.T., et al. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. European Journal of Biochemistry/FEBS 267 April (7) (2000) 2008-2013
83. Triantafilou M., and Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends in Immunology 23 June (6) (2002) 301-304
84. Collins T., Barnoy S., Baqar S., Ranallo R.T., Nemelka K.W., and Venkatesan M.M. Safety and colonization of two novel virG(icsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta). Comparative Medicine 58 February (Number 1) (2008) 88-94
85. Ranallo RT, Kaminski RW,George T, Kordis AA, Chen Q, Szabo K, Venkatesan MM. Virulence, inflammatory potential and adaptive immunity induced by Shigella msbB mutants. Infection and Immunity. 2009 Nov 2, Epub.